7 Most Profitable Biotech Stocks To Buy Right Now
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
Argenx Se (ARGX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 1,238,467 | $761,657,205 | 10.77% | |
| 2. | Citadel Investment Group Ken Griffin | 514,105 | $316,174,575 | -17% | 0.05% |
| 3. | D E Shaw D. E. Shaw | 288,299 | $177,303,885 | +184% | 0.13% |
| 4. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 229,600 | $141,204,000 | -2% | 5.37% |
| 5. | Leucadia National Ian Cumming And Joseph Steinberg | 215,752 | $132,687,480 | +35% | 0.79% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,618,222 | $3,455,206,708 | 0.2% | |
| 2. | 3,069,995 | $1,888,046,925 | 2.84% | |
| 3. | 2,312,358 | $1,422,262,353 | 0.72% | |
| 4. | 1,786,936 | $1,099,001,759 | 0.16% | |
| 5. | 1,068,950 | $657,404,330 | 0.01% |
News See All
Artisan Small Cap Fund Sold argenx SE (ARGX) as it Exceeded Small-Cap Mandate
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.
argenx SE (NASDAQ:ARGX) Q4 2024 Earnings Call Transcript
Operator: Good morning. My name is Rob and I will be your conference operator today. I would like to welcome everyone to the call.
Here’s Why argenx SE (ARGX) Rose in Q4
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.
12 High Growth International Stocks to Invest in Now
On January 15, Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company shared his outlook for 2025.
10 Best Performing Biotech Stocks in 2024
The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and government assistance.
Here's Why argenx SE (ARGX) Surged in Q3
PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S.
Should You Increase Your Holdings in argenx SE (ARGX)?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the letter can be downloaded here.
10 High Growth Healthcare Stocks to Invest in Now
During lean economic times, investing in healthcare stocks is generally regarded as defensive.
10 Best Immunotherapy Stocks to Buy Now
The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by 2033.
Billionaire Hedge Funds
